首页> 外文期刊>BMC Pulmonary Medicine >PROLONG: a cluster controlled trial to examine identification of patients with COPD with poor prognosis and implementation of proactive palliative care
【24h】

PROLONG: a cluster controlled trial to examine identification of patients with COPD with poor prognosis and implementation of proactive palliative care

机译:PROLONG:一项整群对照试验,旨在检查预后不良的COPD患者的识别和积极姑息治疗的实施

获取原文
       

摘要

Background Proactive palliative care is not yet common practice for patients with COPD. Important barriers are the identification of patients with a poor prognosis and the organization of proactive palliative care dedicated to the COPD patient. Recently a set of indicators has been developed to identify those patients with COPD hospitalized for an acute exacerbation who are at risk for post-discharge mortality. Only after identification of these patients with poor prognosis a multi disciplinary approach to proactive palliative care with support of a specialized palliative care team can be initiated. Methods/Design The PROLONG study is a prospective cluster controlled trial in which 6 hospitals will participate. Three hospitals are selected for the intervention condition based on the presence of a specialized palliative care team. The study population consists of patients with COPD and their main informal caregivers. Patients will be included during hospitalization for an acute exacerbation. All patients in the study receive standard care (usual care). Besides, patients in the intervention condition who meet two or more criteria of the set of indicators for proactive palliative care will have additionally regular consultations with a specialized palliative care team. The objectives of the PROLONG study are: 1) to assess the discriminating power of the proposed set of indicators (indicator study) and 2) to assess the effects of proactive palliative care for qualifying patients with COPD on the wellbeing of these patients and their informal caregivers (intervention study). The primary outcome measure of the indicator study is time to death for any cause. The primary outcome measure of the intervention study is the change in quality of life measured by the St George Respiratory Questionnaire (SGRQ) three months after inclusion. Discussion The PROLONG study may lead to better understanding of the conditions to start and the effectiveness of proactive palliative care for patients with COPD. Innovative aspects of the PROLONG study are the use of a set of indicators for proactive palliative care, the active involvement of a specialized palliative care team and the use of a patient-tailored proactive palliative care plan. Trial registration Netherlands Trial Register (NTR): NTR4037
机译:背景技术对于COPD患者,积极的姑息治疗尚未普及。重要的障碍是确定预后不良的患者以及组织专门针对COPD患者的积极姑息治疗。最近,已经开发出一套指标来识别那些因急性加重而住院的COPD患者,这些患者有出院后死亡的风险。只有在识别出这些预后不良的患者后,才能启动多学科方法,在专门的姑息治疗团队的支持下进行积极的姑息治疗。方法/设计PROLONG研究是一项前瞻性集群对照试验,将有6家医院参加。基于专门的姑息治疗团队的存在,选择了三家医院进行干预。研究人群包括COPD患者及其主要的非正式护理人员。住院期间患者会因急性加重而入院。研究中的所有患者均接受标准护理(常规护理)。此外,在干预条件下符合主动姑息治疗指标集的两个或两个以上标准的患者将另外与专门的姑息治疗团队进行定期会诊。 PROLONG研究的目标是:1)评估拟议指标集(指标研究)的区分力; 2)评估对合格的COPD患者进行姑息性姑息治疗对这些患者及其非正式患者的健康的影响照顾者(干预研究)。指标研究的主要结果指标是死于任何原因的时间。干预研究的主要结局指标是入选后三个月,由圣乔治呼吸问卷(SGRQ)衡量的生活质量变化。讨论PROLONG研究可能使人们更好地了解COPD患者的开始条件和积极姑息治疗的有效性。 PROLONG研究的创新之处在于使用了一系列积极的姑息治疗指标,专业的姑息治疗团队的积极参与以及患者定制的积极姑息治疗计划的使用。试用注册荷兰试用注册(NTR):NTR4037

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号